Details for New Drug Application (NDA): 020147

✉ Email this page to a colleague

NDA 020147 describes TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER, which is a drug marketed by Baxter Hlthcare and is included in one NDA. Additional details are available on the TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER profile page.

The generic ingredient in TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER is amino acids; dextrose; magnesium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride. There are three hundred and fifty drug master file entries for this compound. Additional details are available on the amino acids; dextrose; magnesium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride profile page.

Tradename:	TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER
Applicant:	Baxter Hlthcare
Ingredient:	amino acids; dextrose; magnesium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride
Patents:	0

Active Rx/OTC/Discontinued:	DISCN	Dosage:	INJECTABLE;INJECTION			Strength	2.75%;5GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML
Approval Date:	Oct 23, 1995	TE:		RLD:	No

Active Rx/OTC/Discontinued:	DISCN	Dosage:	INJECTABLE;INJECTION			Strength	2.75%;10GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML
Approval Date:	Oct 23, 1995	TE:		RLD:	No

Active Rx/OTC/Discontinued:	DISCN	Dosage:	INJECTABLE;INJECTION			Strength	2.75%;15GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML
Approval Date:	Oct 23, 1995	TE:		RLD:	No

Complete Access Available with Subscription